Astellas Pharma Gmbh

Tdk Corporation

California Institute of Technology

Yamanouchi Pharmaceutical Company Ltd.

Mitobridge, Inc.

Kenji Negoro

Hiroaki Tanaka

Hajime Takamatsu

Taisuke Takahashi

Shigeru Yoshida

Jun Maeda

Masahiko Hayakawa

Takanori Koike

Kazuhiro Yokoyama

Yasuhiro Yonetoku

Daisuke Sasuga

Brian M Stoltz

Hiroyuki Moritomo

Scott C Virgil

Christopher D Gilmore

Kenichi Onda

Christian Gruenanger

Takahiro Nigawara

Kazuhiko Iikubo

Guillaume Lapointe

Kevin McCormack Allan

Gerit Maria Pototschnig

Takahide Ohishi

Eric R Welin

Pamela Tadross

Aurapat (Fa) Ngamnithiporn

Max Klatte

Christopher Haley

Emil Glibstrup

Takashi Kamikubo

Norio Seki

Shuichi Sakamoto

Satoshi Miyamoto

Takayuki Suzuki

Fukushi Hirayama

Ryushi Seo

Tatsuya Maruyama

Akio Kamikawa

Yusuke Inagaki

Wataru Hamaguchi

Issei Tsukamoto

Takatoshi Soga

Ken-Ichi Suzuki

Norio Asai

Daisuke Kaga

Jiro Fujiyasu

Satoshi Hayashibe

Masamichi Okada

Ikumi Kuriwaki

Kei Ohnuki

Michinori Akaiwa

Hisashi Mihara

Toshio Kurosaki

Akinori Hariya

Hirotsune Itahana

Fumiyoshi Iwasaki

Kyoichi Maeno

Junko Maeda

Jeffrey Ciavarri

Kazuhito Tanabe

Itsuro Shimada

Aurapat Ngamnithiporn

Yumi Yamashita

Atsuyuki Kohara

Kai Kitamura

Kenichi Kakefuda

Masanobu Tabuchi

Ryosuke Nakano

Hideyoshi Fuji

Kiyoshi Yahiro

A coil structure includes a first winding portion and a second winding portion disposed so as to overlap each other with winding axes substantially parallel to each other. The first winding portion and the second winding portion have regions overlapping each other when viewed from a winding axis direction. The second winding portion has a rising portion extending in a cross section perpendicular to a direction of a current flowing through a conductor constituting the winding portion with a directional component away from the first winding portion included.

Coil structure

[Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.

Aryl alkynamide derivatives

A current detection circuit capable of compensating for detection accuracy of a switching current through switching of a connection state of a resistor even when the switching current has a component in a direction opposite to a predetermined direction is provided. A current detection circuit for detecting a value of a component in a predetermined direction of a switching current using a current transformer, wherein, when the switching current flowing in a primary side of the current transformer has a component in a direction opposite to the predetermined direction, a connection state of reset elements on a secondary side of the current transformer is switched such that an impedance of a magnetic reset on the secondary side of the current transformer is decreased.

Current detection circuit, power conversion device, and power system

[Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic Mreceptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic Mreceptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic Mreceptor, for example voiding dysfunction such as underactive bladder.

2-acylaminothiazole derivative or salt thereof

(&#x2212;)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided.

Methods for preparing bis-tetrahydroisoquinoline-containing compounds

A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic Mreceptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic Mreceptor, thereby completing the present invention. 2-aminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic Mreceptor, for example voiding dysfunction such as underactive bladder.

2-aminothiazole derivative or salt thereof

Thiazole derivatives having pyrazine-2-carbonylamino substituted at the 2-position of the following formula (I): are excellent muscarinic Mreceptor positive allosteric modulators, and are useful for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic Mreceptor. The 2-acylaminothiazole derivatives and salts thereof can be used for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic Mreceptor, for example, voiding dysfunctions such as underactive bladder.

Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli. Means for Solution: Benzene derivatives or their salts having a characteristic chemical structure with a phenol ring and a benzene ring bonding to each other via an amide bond, in which the phenol ring further bonds to a benzene ring or a heteroaryl ring via an amide bond. They have an excellent effect of inhibiting the activated blood coagulation factor X, and especially have an excellent oral activity.

Benzene derivative or salt thereof

A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.

Oxadiazolidinedione compound

The present invention provides a condensed pyrimidine compound represented by formula (I) or pharmaceutically acceptable salt thereof: where A represents a ring where at least one carbon atom within said ring is optionally substituted with one or more groups selected from the group consisting of lower alkyl, &#x2014;O-(lower alkyl), halogen atom, carboxyl, &#x2014;CO-(lower alkyl), and carbamoyl, Rrepresents: (1) phenyl substituted with at least three halogen atoms, which may have at least one additional substituent, or (2) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, each of which is optionally substituted; and Rrepresents a group represented by formula (II) or an optionally substituted cyclic amino: wherein Rand Rmay be identical or different and each represents &#x2014;H, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, heteroaryl, non-aromatic heterocyclyl, or &#x2014;O-(lower alkyl), each of which is optionally substituted.

Pyrimidine derivative condensed with a non-aromatic ring

There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

Aromatic-ring-fused pyrimidine derivative

Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.

2-cyano-4-fluoropyrrolidine derivative or its salt

Thiazolobenzoimidazole derivatives

Growing community of inventors

Tokyo, Japan

Kenji Negoro